STIM
Neuronetics, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$2.88
+5.88%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−13.7x
Market Cap
$219.45M
MomentumView details →
1D Return
+5.88%
YTD Return
+112.32%
RSI (14)
58.5
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−13.7x
Market Cap
$219.45M
RSI (14)
58.5
MomentumView details →
1D Return
+5.88%
YTD Return
+112.32%
SummaryUpdated Jun 1, 2026
Neuronetics, Inc. (NASDAQ:STIM) is a commercial-stage medical technology company founded in 2001 and headquartered in Malvern, Pennsylvania. The company went public in June 2018 and has evolved from a pure medical device manufacturer into a vertically integrated mental health care provider through its 2024 acquisition of Greenbrook TMS. Neuronetics specializes in non-invasive brain stimulation therapies for treating various neurohealth disorders, with a primary focus on depression treatment through its flagship NeuroStar Advanced Therapy System.
Similar companies
Latest newsMore news →
Nir Naor was appointed Executive Vice President, Chief Financial Officer, and Treasurer of Neuronetics, Inc., effective July 23, 2026, and subsequently became principal financial and accounting officer on August 12, 2026, succeeding Francis X. Brown III as interim principal financial and accounting officer.19d agoNeuronetics introduced additional commercial purchasing options for its NeuroStar transcranial magnetic stimulation (TMS) systems.24d ago